Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO).

about

Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO).

Item

http://www.wikidata.org/entity/Q54982410

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Anti PD-L1 DUrvalumab combined ...... k: A phase I/II study (DUCRO).

@en

Anti PD-L1 DUrvalumab combined ...... d and neck: A phase I/II study

@nl

type

Item

label

Anti PD-L1 DUrvalumab combined ...... k: A phase I/II study (DUCRO).

@en

Anti PD-L1 DUrvalumab combined ...... d and neck: A phase I/II study

@nl

prefLabel

Anti PD-L1 DUrvalumab combined ...... k: A phase I/II study (DUCRO).

@en

Anti PD-L1 DUrvalumab combined ...... d and neck: A phase I/II study

@nl

P1476

Anti PD-L1 DUrvalumab combined ...... k: A phase I/II study (DUCRO).

@en

P2093

Daniela Greto

http://www.w3.org/2001/XMLSchema#string

Lorenzo Livi

http://www.w3.org/2001/XMLSchema#string

Mariangela Sottili

http://www.w3.org/2001/XMLSchema#string

Mauro Loi

http://www.w3.org/2001/XMLSchema#string

P2860

Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy

Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.

Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.

Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen

Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas.

P304

42-47

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CTRO.2018.01.005

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-02-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29594250

http://www.w3.org/2001/XMLSchema#string

P921

cetuximab

P932

5862684

http://www.w3.org/2001/XMLSchema#string